Response, Remission, Relapse: Decoding Psilocybin Depression Results

Psilocybin findings can be promising without answering every patient question. This source-based guide examines psilocybin depression outcomes while separating supervised research from claims about personal benefit or commercial access.

Response is improvement, not necessarily recovery

Response generally means symptoms decrease by a specified amount. In a 2022 follow-up, it meant at least 50 percent reduction on the measure used. A person can cross that threshold with substantial symptoms remaining. Starting severity matters: halving a very high score does not necessarily leave someone functioning comfortably.

Remission describes an assessment

Remission means symptoms below a defined cutoff, not permanent cure or no need for further care. The small 2022 study followed 24 treatment completers receiving psilocybin with supportive psychotherapy. At twelve months 75 percent met response and 58 percent remission criteria. These describe that group at that assessment, not personal probabilities for everyone seeking access.

Follow-up changes causal interpretation

The original immediate-versus-delayed design had no continuing untreated comparison at long-term follow-up. Other care, life events and natural course may influence later improvement. A 2024 six-month comparative follow-up was also observational. Randomization at the start does not control everything happening afterward, and sustained improvement should not automatically be attributed solely to the drug.

Questions behind the headline

Check definitions, assessed numbers, duration and whether a comparator remained. Look for whether percentages concern all entrants or completers. Relapse needs a definition and repeated measurement; it cannot be inferred from one remission assessment. Trial results concern a supervised package, not any commercial session. Ask about function as well as symptoms, while remembering legal availability and medical approval are distinct from guaranteed lasting recovery.

This article is informational, not an individualized treatment recommendation. A qualified clinician can interpret the evidence alongside your diagnosis, history and existing care. Do not alter prescribed treatment based on a study summary.

Sources

• Gukasyan et al., 2022: Twelve-month follow-up
• Erritzoe et al., 2024: Comparative follow-up

This article is for general information, not individual medical advice. Illustration is AI-generated and does not depict actual study participants.